JP2007530543A - 間葉幹細胞及びその使用法 - Google Patents

間葉幹細胞及びその使用法 Download PDF

Info

Publication number
JP2007530543A
JP2007530543A JP2007505005A JP2007505005A JP2007530543A JP 2007530543 A JP2007530543 A JP 2007530543A JP 2007505005 A JP2007505005 A JP 2007505005A JP 2007505005 A JP2007505005 A JP 2007505005A JP 2007530543 A JP2007530543 A JP 2007530543A
Authority
JP
Japan
Prior art keywords
animal
cells
mesenchymal stem
stem cells
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007505005A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007530543A5 (https=
Inventor
ピッテンジャー，マーク，エフ．
アガワル，スディープタ
Original Assignee
オシリス セラピューティクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39772836&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2007530543(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by オシリス セラピューティクス，インコーポレイテッド filed Critical オシリス セラピューティクス，インコーポレイテッド
Publication of JP2007530543A publication Critical patent/JP2007530543A/ja
Publication of JP2007530543A5 publication Critical patent/JP2007530543A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0664—Dental pulp stem cells, Dental follicle stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0666—Mesenchymal stem cells from hair follicles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
JP2007505005A 2004-03-22 2005-03-15 間葉幹細胞及びその使用法 Pending JP2007530543A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55511804P 2004-03-22 2004-03-22
PCT/US2005/008506 WO2005093044A1 (en) 2004-03-22 2005-03-15 Mesenchymal stem cells and uses therefor
US11/541,853 US20080213227A1 (en) 2004-03-22 2006-10-02 Mesenchymal stem cells and uses therefor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012058539A Division JP6114500B2 (ja) 2004-03-22 2012-03-15 間葉幹細胞及びその使用法

Publications (2)

Publication Number Publication Date
JP2007530543A true JP2007530543A (ja) 2007-11-01
JP2007530543A5 JP2007530543A5 (https=) 2008-04-24

Family

ID=39772836

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007505005A Pending JP2007530543A (ja) 2004-03-22 2005-03-15 間葉幹細胞及びその使用法
JP2009530402A Pending JP2010505764A (ja) 2004-03-22 2007-09-26 間葉系幹細胞とその用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009530402A Pending JP2010505764A (ja) 2004-03-22 2007-09-26 間葉系幹細胞とその用途

Country Status (8)

Country Link
US (21) US20050239897A1 (https=)
EP (10) EP3461884B1 (https=)
JP (2) JP2007530543A (https=)
KR (1) KR20090065478A (https=)
CN (1) CN101384702A (https=)
AU (3) AU2005227295A1 (https=)
CA (2) CA2564679C (https=)
WO (2) WO2005093044A1 (https=)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009242265A (ja) * 2008-03-28 2009-10-22 Jcr Pharmaceuticals Co Ltd アトピー性皮膚炎治療剤
JP2011505860A (ja) * 2007-12-21 2011-03-03 ボーン セラピューティクス エス．アー． 炎症性リウマチ性疾患の治療におけるヒト骨形成細胞
JP2011529957A (ja) * 2008-08-04 2011-12-15 セレリックス エスエー 間葉系幹細胞の使用
JP2013526839A (ja) * 2009-12-08 2013-06-27 ザ ボード オブ トラスティーズ オブ ザ ユニバシティ オブ イリノイズ 幹細胞免疫変調の使用方法及び装置
JP2016516985A (ja) * 2013-03-15 2016-06-09 ティゲニクス、エセ、ア、ウＴｉＧｅｎｉｘ，Ｓ．Ａ．Ｕ． 細胞治療に対する臨床反応を決定するためのリンパ球バイオマーカー
JP2016540969A (ja) * 2013-11-04 2016-12-28 ベクトン・ディキンソン・アンド・カンパニーＢｅｃｔｏｎ， Ｄｉｃｋｉｎｓｏｎ Ａｎｄ Ｃｏｍｐａｎｙ 多能性間質細胞集団の免疫調節ポテンシャル
WO2017221879A1 (ja) * 2016-06-20 2017-12-28 富士フイルム株式会社 トロフィックファクタ放出剤および炎症疾患処置剤
WO2019146131A1 (ja) * 2018-01-24 2019-08-01 学校法人順天堂大学 間葉系幹細胞による処置の効果を増幅するための組成物
JP2019531281A (ja) * 2016-09-07 2019-10-31 エスシーエム ライフサイエンス カンパニー リミテッド 炎症刺激された間葉系幹細胞を含む免疫疾患または炎症疾患の予防または治療用薬学的組成物
JP2021526135A (ja) * 2018-06-05 2021-09-30 メディポスト・カンパニー・リミテッドＭｅｄｉｐｏｓｔ Ｃｏ．， Ｌｔｄ． 有効成分として間葉系幹細胞を含む炎症性疾患の予防又は治療のための医薬組成物
JP2022035914A (ja) * 2020-08-21 2022-03-04 遵義医科大学附属医院 高速かつ効率的にインビトロ増幅ヒト間葉系幹細胞的方法および使用
JP2022528827A (ja) * 2019-03-15 2022-06-16 フラウンホーファー－ゲゼルシャフト ツゥア フェアデルング デア アンゲヴァンドテン フォァシュング エー．ファウ． 体外免疫寛容増強血液治療のための治療装置及び方法

Families Citing this family (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7514074B2 (en) * 1997-07-14 2009-04-07 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
DK1349918T3 (da) 2000-12-06 2014-11-10 Anthrogenesis Corp Fremgangsmåde til indsamling af stamceller fra moderkagen
AUPR298901A0 (en) 2001-02-07 2001-03-08 McComb Foundation, Inc., The Cell suspension preparation technique and device
EP2316919B1 (en) * 2001-02-14 2015-10-07 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
EP3246396B1 (en) * 2001-02-14 2020-01-29 Celularity, Inc. Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells
US9969980B2 (en) 2001-09-21 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
EP3461884B1 (en) 2004-03-22 2025-05-28 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
TR201901268T4 (tr) * 2004-03-22 2019-02-21 Mesoblast Int Sarl Mezenkimal kök hücreleri ve bunların kullanımları.
US20080095749A1 (en) * 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
ES2313805B1 (es) 2004-10-04 2009-12-23 Cellerix, S.L. Identificacion y aislamiento de celulas multipotentes de tejido mesenquimal no osteocondral.
US20060045872A1 (en) 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
KR20080105555A (ko) * 2007-05-31 2008-12-04 인하대학교 산학협력단 중간엽 골수세포를 이용한 이식편대숙주질환 치료제 및치료방법
KR101536239B1 (ko) 2005-09-23 2015-07-13 셀레릭스, 에스.엘. 면역조절활성을 갖는 세포 개체군, 분리 방법 및 용도
DK1957633T3 (en) 2005-10-13 2014-03-17 Anthrogenesis Corp Immunomodulation USING PLACE SPEECH STEM CELLS
PT2471904T (pt) 2005-12-29 2019-02-25 Celularity Inc População de células estaminais placentárias
CN101389754A (zh) 2005-12-29 2009-03-18 人类起源公司 胎盘干细胞和第二来源干细胞的联合培养
US20070258963A1 (en) * 2006-01-13 2007-11-08 Osiris Therapeutics, Inc. Mesenchymal stem cells expressing TNF-alpha receptors
US20070178073A1 (en) * 2006-02-01 2007-08-02 Samsung Life Public Welfare Foundation Composition Comprising Separated or Proliferated Cells from Umbilical Cord Blood for Treating Developmental and/or Chronic Lung Disease
US20070207130A1 (en) * 2006-03-01 2007-09-06 Calvin Cao Stem cell therapy to treat symptoms of avian flu and other diseases
AU2007243221A1 (en) * 2006-04-28 2007-11-08 Tulane University Health Sciences Center Methods for treating diabetes
US9598673B2 (en) * 2006-05-19 2017-03-21 Creative Medical Health Treatment of disc degenerative disease
US7993918B2 (en) 2006-08-04 2011-08-09 Anthrogenesis Corporation Tumor suppression using placental stem cells
GB0619500D0 (en) * 2006-10-03 2006-11-08 Univ Keele Treatment of fibrosis
AU2008216748A1 (en) 2007-02-12 2008-08-21 Anthrogenesis Corporation Hepatocytes and chondrocytes from adherent placental stem cells; and CD34+, CD45- placental stem cell-enriched cell populations
EP3763376A1 (en) 2007-02-12 2021-01-13 Celularity, Inc. Treatment of inflammatory diseases using placental stem cells
US8983570B2 (en) 2007-03-27 2015-03-17 Cardiovascular Biotherapeutics, Inc. Therapeutic angiogenesis for treatment of the spine
US11224635B2 (en) * 2007-03-27 2022-01-18 Venturis Thereuptics, Inc. Therapeutic angiogenesis for treatment of the spine and other tissues
US20080254005A1 (en) * 2007-04-06 2008-10-16 Medistem Labortories Stem Cell Therapy for the Treatment of Autism and Other Disorders
US20080260703A1 (en) * 2007-04-23 2008-10-23 Medistem Labortories Treatment of Insulin Resistance and Diabetes
WO2008150368A1 (en) * 2007-05-24 2008-12-11 Apceth Gmbh & Co. Kg Cd34 stem cell-related methods and compositions
EP2171043B1 (en) * 2007-06-15 2015-03-18 Garnet BioTherapeutics, Inc Treatment of diseases and disorders using self-renewing colony forming cells cultured and expanded in vitro
US9200253B1 (en) 2007-08-06 2015-12-01 Anthrogenesis Corporation Method of producing erythrocytes
US20090324609A1 (en) 2007-08-09 2009-12-31 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
EP2191835A4 (en) 2007-09-07 2011-12-14 Japan Chem Res THERAPEUTIC AND PROPHYLACTIC AGENTS FOR ARTHRITIS
US8741315B2 (en) * 2007-09-12 2014-06-03 Yeda Research And Development Co. Ltd. Methods of treating tumors in immune-privileged sites
MX2010003019A (es) 2007-09-19 2010-04-30 Pluristem Ltd Celulas adherentes de los tejidos adiposo y de placenta y uso de las mismas en la terapia.
NZ599825A (en) 2007-09-28 2014-10-31 Anthrogenesis Corp Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
WO2009046377A2 (en) * 2007-10-04 2009-04-09 Medistem Laboratories, Inc. Compositions and methods of stem cell therapy for autism
DK2205721T3 (en) 2007-10-17 2016-10-24 Txcell TR1 cells mesenchymal stem cells and uses thereof
WO2009065093A2 (en) * 2007-11-17 2009-05-22 University Of Medicine And Dentistry Of New Jersey Use of stem cells for wound healing
US9011840B2 (en) 2008-03-14 2015-04-21 The Board Of Trustees Of The University Of Illinois Activated mesenchymal stem cells for wound healing and impaired tissue regeneration
US20110044958A1 (en) * 2008-03-14 2011-02-24 The Board Of Trustees Of The University Of Illinois Activated mesenchymal stem cells for the prevention and repair of inflammatory states
EP2279246A4 (en) * 2008-05-02 2012-03-28 Massachusetts Inst Technology METHOD AND COMPOSITIONS FOR MODULATING IMMUNOLOGICAL TOLERANCE
BRPI0909541A2 (pt) 2008-05-27 2016-10-11 Pluristem Ltd ''método para tratamento de doenças inflamatórias do cólon''
AU2015268704B2 (en) * 2008-08-04 2017-08-10 Consejo Superior De Investigaciones Cientificas Uses of mesenchymal stem cells
EP3124601A1 (en) * 2008-08-14 2017-02-01 Mesoblast International Sàrl Purified mesenchymal stem cell compositions and methods of purifying mesenchymal stem cell compositions
KR20240052847A (ko) 2008-08-20 2024-04-23 셀룰래리티 인코포레이티드 개선된 세포 조성물 및 그의 제조 방법
WO2010021715A1 (en) 2008-08-20 2010-02-25 Anthrogenesis Corporation Treatment of stroke using isolated placental cells
CA2734446C (en) 2008-08-22 2017-06-20 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
KR20100054711A (ko) * 2008-11-14 2010-05-25 메디포스트(주) 간엽 줄기세포 또는 이의 배양액을 포함하는 신경질환의 예방 또는 치료용 조성물
WO2010056336A1 (en) * 2008-11-14 2010-05-20 Howmedica Osteonics Corp. Cells for joint fluid
AU2009316541B2 (en) 2008-11-19 2015-08-06 Celularity Inc. Amnion derived adherent cells
US9192695B2 (en) 2008-11-20 2015-11-24 Allosource Allografts combined with tissue derived stem cells for bone healing
US8309343B2 (en) 2008-12-01 2012-11-13 Baxter International Inc. Apparatus and method for processing biological material
US10098333B2 (en) * 2008-12-09 2018-10-16 University Of Southern California Method for treating an SLE-like autoimmune disease in a human subject consisting of administering stem cells from human exfoliated deciduous teeth (SHED) and erythropoietin (EPO) to said human subject
US8586360B2 (en) 2009-07-02 2013-11-19 Anthrogenesis Corporation Method of producing erythrocytes without feeder cells
WO2011011500A1 (en) * 2009-07-21 2011-01-27 Abt Holding Company Use of stem cells to reduce leukocyte extravasation
WO2011020095A2 (en) * 2009-08-14 2011-02-17 Case Western Reserve University Compositions and methods of treating inflammation
WO2011047345A2 (en) * 2009-10-15 2011-04-21 Tai June Yoo Methods of treating diseases of conditions using mesenchymal stem cells
KR101301262B1 (ko) * 2009-10-23 2013-08-27 가톨릭대학교 산학협력단 ＴＧＦβ를 코딩하는 뉴클레오티드 서열이 도입된 간엽줄기세포 및 그의 용도
CN102048756B (zh) * 2009-11-04 2014-02-19 中国医学科学院基础医学研究所 人脂肪来源的间充质干细胞在肾脏、眼底疾病中的用途
US20130129686A1 (en) * 2009-11-19 2013-05-23 Regents Of The University Reducing Inflammation Using Cell Therapy
DK3284818T3 (da) 2010-01-26 2022-06-20 Celularity Inc Behandling af knoglerelateret kræft ved hjælp af placenta stamceller
DK2539436T3 (da) * 2010-02-25 2021-10-18 Abt Holding Co Modulering af makrofagaktivering
LT2556145T (lt) 2010-04-07 2016-11-10 Anthrogenesis Corporation Angiogenezė naudojant placentos kamienines ląsteles
MX2012011543A (es) 2010-04-08 2013-05-06 Anthrogenesis Corp Tratamiento de sarcoidosis empleando celulas madre placentarias.
SG185526A1 (en) 2010-05-12 2012-12-28 Abt Holding Co Modulation of splenocytes in cell therapy
EP2575831B1 (en) * 2010-05-27 2016-04-20 Pluristem Ltd. Skeletal muscle regeneration using mesenchymal stem cells
US20120020931A1 (en) * 2010-06-02 2012-01-26 Rutgers, The State University Of New Jersey Therapeutic encapsulated embryonic stem cells and mesenchymal stromal cells
ES2666746T3 (es) 2010-07-13 2018-05-07 Anthrogenesis Corporation Métodos para generar linfocitos citolíticos naturales
US9682105B2 (en) * 2010-07-14 2017-06-20 University Of Southern California Methods of promoting wound healing and attenuating contact hypersensitivity with gingiva-derived mesenchymal stem cells
PT2611906T (pt) * 2010-08-31 2024-04-16 Gallant Pet Inc Terapias sistémicas com células estaminais alogénicas para tratamento de doenças em gatos e cães
US20120087868A1 (en) 2010-10-08 2012-04-12 Gabriele Todd Nanoparticle-loaded cells
US8969315B2 (en) 2010-12-31 2015-03-03 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules
US20140154274A1 (en) * 2011-01-12 2014-06-05 Tigenix Nv Methods and compositions for use in intralymphatic cellular therapies
CA2824553A1 (en) 2011-01-19 2012-07-26 The Regents Of The University Of California Somatic cells with innate potential for pluripotency
KR20120095022A (ko) * 2011-02-18 2012-08-28 가톨릭대학교 산학협력단 간엽줄기세포 및 면역조절 ｔ 세포를 유효성분으로 포함하는 이식편대숙주질환 예방 또는 치료용 세포치료제 조성물
US20120288480A1 (en) * 2011-02-22 2012-11-15 Taipei Medical University Cell population comprising orbital fat-derived stem cells (ofscs) and their isolation and applications
US8709401B2 (en) 2011-02-25 2014-04-29 Howmedica Osteonics Corp. Primed stem cells and uses thereof to treat inflammatory conditions in joints
JP6104896B2 (ja) 2011-06-01 2017-03-29 アントフロゲネシス コーポレーション 胎盤幹細胞を使用する疼痛の治療
WO2013055476A1 (en) 2011-09-09 2013-04-18 Anthrogenesis Corporation Treatment of amyotrophic lateral sclerosis using placental stem cells
SI2785359T1 (sl) 2011-11-30 2018-11-30 Astellas Institute For Regenerative Medicine Mezenhimske stromalne celice in uporabe povezane z njimi
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
CA2857686C (en) 2011-12-09 2023-01-17 Metabolic Pharmaceuticals Pty Ltd Use of growth hormone fragments
CN102552880A (zh) * 2011-12-14 2012-07-11 南方医科大学 一种促进皮肤创面愈合的生物制剂
CN103191154B (zh) * 2012-01-06 2015-09-09 上海交通大学医学院 充质干细胞及其提取方法在制备银屑病的药物中的应用
GB201202319D0 (en) 2012-02-10 2012-03-28 Orbsen Therapeutics Ltd Stromal stem cells
EP4699624A3 (en) * 2012-03-22 2026-05-06 AVITA Medical Americas, LLC Cell suspension and use thereof
WO2013146992A1 (ja) 2012-03-29 2013-10-03 日本ケミカルリサーチ株式会社 歯髄由来の多能性幹細胞の製造方法
HK1208054A1 (en) 2012-07-12 2016-02-19 爱姆斯坦生物技术公司 Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
WO2014018230A2 (en) * 2012-07-25 2014-01-30 Albert Einstein College Of Medicine Of Yeshiva University Methods to isolate human mesenchymal stem cells
CN103585177A (zh) * 2012-08-13 2014-02-19 首都医科大学附属北京口腔医院 间充质干细胞和基因修饰的间充质干细胞的用途
US10357538B2 (en) 2012-12-24 2019-07-23 Northern Sydney Local Health District Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
WO2014113704A2 (en) * 2013-01-18 2014-07-24 Escape Therapeutics, Inc. Enhanced differentiation of mesenchymal stem cells
CN115137753A (zh) 2013-02-05 2022-10-04 细胞结构公司 来自胎盘的自然杀伤细胞
SG11201506312TA (en) 2013-02-12 2015-09-29 Replicel Life Sciences Inc Compositions and methods for treating and repairing tendons
US20140271568A1 (en) * 2013-03-12 2014-09-18 Hawking Biological Technology Co., Ltd Method and kit for providing an increased expression of telomerase, brain-derived neurotrophic factor, stromal cell-derived factor-1, cxc chemokine receptor 4, and/or immune regulatory factor of stem cell
WO2014143383A1 (en) 2013-03-13 2014-09-18 Agilent Technologies, Inc. Transposome tethered to a gene delivery vehicle
AU2013205148B2 (en) 2013-03-14 2014-10-30 AVITA Medical Americas, LLC Systems and methods for tissue processing and preparation of cell suspension therefrom
CA2899713C (en) 2013-03-15 2022-07-19 Allosource Cell repopulated collagen matrix for soft tissue repair and regeneration
IL289870B2 (en) 2013-04-12 2023-03-01 Lafrancesca Saverio Improving organs for transplantation
CN104138391B (zh) * 2013-05-08 2018-07-31 中国科学院上海生命科学研究院 间充质干细胞在预防或治疗应激反应导致的免疫力下降中的应用
US20160129531A1 (en) * 2014-01-13 2016-05-12 Camarc Llc Electrode of a welding torch
WO2015123477A1 (en) 2014-02-12 2015-08-20 Replicel Life Sciences Inc. Compositions and methods for treating bone, joints and cartilage
US10624930B2 (en) * 2014-06-10 2020-04-21 Mesoblast International Sarl Treatment of immune disorders
JP6722599B2 (ja) * 2014-06-30 2020-07-15 ティジェニクス エス．エー．ユー． 全身性炎症反応症候群の治療のための間葉系間質細胞
JP6452107B2 (ja) 2014-09-05 2019-01-16 国立大学法人 東京大学 糖尿病性皮膚潰瘍治療のための多能性幹細胞
TWI625391B (zh) 2014-09-17 2018-06-01 國璽幹細胞應用技術股份有限公司 藁本內酯之應用
US20160095885A1 (en) 2014-10-01 2016-04-07 WibiWorks Therapeutics, Inc. Induction Medium & Methods for Stem Cell Culture & Therapy
CN104357383A (zh) * 2014-10-11 2015-02-18 张炳强 人脂肪间充质干细胞制备方法及其在制备疾病药物的应用
RU2644650C2 (ru) 2014-12-01 2018-02-13 Общество с ограниченной ответственностью "Т-Хелпер Клеточные Технологии" Материал стволовых клеток и способ его получения
US20180099009A1 (en) * 2015-03-20 2018-04-12 Rediens, Inc. Bony Tissue Delivery Systems and Methods
US10124038B2 (en) 2015-03-20 2018-11-13 Orbsen Therapeutics Limited Modulators of syndecan-2 and uses thereof
US10746729B2 (en) * 2015-04-24 2020-08-18 Tigenix, S.A.U. Biomarkers for determining the clinical response to cell therapy
JP6992983B2 (ja) 2015-09-15 2022-01-13 カンステム バイオテック カンパニー リミテッド Ｓｏｄ３を過剰発現する幹細胞を有効成分として含む炎症性疾患の予防又は治療用組成物
US12171786B2 (en) 2015-10-05 2024-12-24 The Regents Of The University Of California Use of mesenchymal stem cells for the treatment of inflammation
EP3402489B1 (en) 2016-01-15 2021-06-09 Orbsen Therapeutics Limited Sdc-2 exosome compositions and methods of isolation and use
NZ745530A (en) 2016-01-21 2023-03-31 Abt Holding Co Stem cells for wound healing
GB201604304D0 (en) 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
US11174461B2 (en) 2016-03-16 2021-11-16 Cynata Therapeutics Limited Colony forming medium and use thereof
RU2708329C2 (ru) 2016-05-31 2019-12-05 Общество с ограниченной ответственностью "Т-Хелпер Клеточные Технологии" Материал стволовых клеток, композиции и способы применения
JP7105195B2 (ja) 2016-11-15 2022-07-22 株式会社カネカ 胎児付属物に由来する間葉系幹細胞を含む細胞集団とその製造方法、及び医薬組成物
US10987381B2 (en) * 2017-01-27 2021-04-27 Neil Riordan Mesenchymal stem cells with enhanced efficacy in treatment of autoimmunity particularly rheumatoid arthritis
CA3069805A1 (en) 2017-07-14 2019-01-17 Orbsen Therapeutics Limited Cd39 stromal stem cells methods of isolation and use
SG11202004680UA (en) 2017-11-22 2020-06-29 Mesoblast Int Sarl Cellular compositions and methods of treatment i
ES2985827T3 (es) 2017-12-22 2024-11-07 Chiesi Farm Spa Células estromales mesenquimales y procedimientos de obtención de células estromales mesenquimales a partir del cordón umbilical
EP3750987A4 (en) 2017-12-28 2021-11-10 Kaneka Corporation CELL POPULATION INCLUDING ADHESIVE STEM CELLS, ITS PRODUCTION PROCESS, AND PHARMACEUTICAL COMPOSITION
US20210154230A1 (en) * 2018-05-04 2021-05-27 Spinalcyte, Llc Intradiscal t-regulatory cell administration for treatment of disc degenerative disease
CN108646035B (zh) * 2018-05-18 2021-06-11 北京亦科诺生物科技有限公司 胰岛素样生长因子1的新应用
CA3103570A1 (en) * 2018-06-14 2019-12-19 Abraham J And Phyllis Katz Cord Blood Foundation Isolation of mesenchymal stromal cells from umbilical cord blood
WO2020071429A1 (ja) * 2018-10-04 2020-04-09 国立研究開発法人物質・材料研究機構 血管新生促進剤、及び治療方法
US20220333197A1 (en) * 2019-01-31 2022-10-20 Primegen Biotech, Llc Treatment of Atopic Dermatitis Using Mesenchymal Stem Cells and Immune Modulation
TW202045716A (zh) * 2019-02-28 2020-12-16 澳大利亞商辛那塔治療有限公司 用於改善間葉幹細胞之血管生成潛力的方法
US20220154147A1 (en) * 2019-03-12 2022-05-19 Global Stem Cell Technology Immunomodulating mesenchymal stem cells
EP3943091A4 (en) * 2019-03-19 2022-12-07 SCM Lifescience Co., Ltd. METHOD OF TREATMENT OF ATOPIC DERMATITIS USING MONOCLONAL STEM CELLS
RU2704322C1 (ru) * 2019-06-11 2019-10-28 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Крем с секретомом мультипотентных мезенхимальных стромальных клеток для коррекции псориазиформного воспаления в эксперименте
EP3984596A4 (en) 2019-06-14 2023-06-21 Kaneka Corporation POPULATION OF CELLS COMPRISING MESENCHYMATOUS CELLS, PHARMACEUTICAL COMPOSITION COMPRISING THEM AND METHOD FOR PRODUCTION THEREOF
CA3170255A1 (en) * 2020-03-05 2021-09-10 Silviu Itescu Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells
EP4137141A4 (en) * 2020-04-13 2024-04-24 National University Corporation Tokai National Higher Education and Research System AGENT FOR INCREASING CD25-POSITIVE REGULATORY T CELLS IN THE KIDNEY
AU2021267900A1 (en) 2020-05-08 2023-01-19 Gallant Pet Inc. Uterine-derived regenerative cell compositions and uses thereof
CN111557952A (zh) * 2020-05-28 2020-08-21 澳门大学 间充质干细胞在制备用于促进脂肪移植的制剂中的应用
CN112076217A (zh) * 2020-10-26 2020-12-15 重庆医科大学附属第一医院 一种间充质干细胞来源的抗炎症氧化脂质组合物的制备方法
JP2024517954A (ja) * 2021-05-13 2024-04-23 プライムジェン ユーエス インコーポレイテッド 肝疾患を治療するための方法および組成物
IL312434A (en) * 2021-11-01 2024-06-01 Mam Holdings Of West Florida L L C Mesenchymal stem cells for the prevention and targeted treatment of cancer and other diseases
CN115433709A (zh) * 2022-06-13 2022-12-06 南京艾尔普再生医学科技有限公司 一种用于预测心肌细胞移植免疫排斥反应的体外实验模型
US12570949B2 (en) 2022-12-27 2026-03-10 AVITA Medical Americas, LLC Systems and devices for wound therapy and related methods of use
DE202023002794U1 (de) 2022-12-27 2024-07-15 AVITA Medical Americas, LLC Kassette zur Herstellung einer regenerativen epidermalen Suspension
USD1112812S1 (en) 2023-12-22 2026-02-10 AVITA Medical Americas, LLC Tissue processing cartridge
CN119235919B (zh) * 2024-12-06 2025-04-11 四川华大生命科技有限公司 一种用于修复糖尿病创面的干细胞培养物制剂的制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6048933A (ja) * 1983-08-29 1985-03-16 Green Cross Corp:The ガンマ−・インタ−フェロン組成物
JP2003137898A (ja) * 2002-08-01 2003-05-14 Hayashibara Biochem Lab Inc 免疫担当細胞においてインターフェロン−γの産生を誘導する因子（ＩＧＩＦ）
JP2003520254A (ja) * 2000-01-19 2003-07-02 エス． ジル，パーカッシュ アンチセンスｖｅｇｆオリゴヌクレオチドに関する方法および組成物
JP2004506598A (ja) * 1999-10-26 2004-03-04 オシリス　セラピューティクス，インコーポレイテッド 移植における免疫応答の予防および処置に適した間葉幹細胞から獲得した上澄み
JP2004507454A (ja) * 2000-04-25 2004-03-11 オシリス　セラピューティクス，インコーポレイテッド 間葉幹細胞を用いる関節修復
JP2006510675A (ja) * 2002-12-05 2006-03-30 ケース ウエスタン リザーブ ユニバーシティ 虚血の細胞ベースの治療

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6048933U (ja) 1983-09-12 1985-04-06 株式会社大隈鐵工所 研削盤ベツド上面のしぶき止めカバ−
WO1987005518A1 (en) 1986-03-17 1987-09-24 Schering Corporation Treatment of cancers with gamma interferon
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US6010696A (en) * 1990-11-16 2000-01-04 Osiris Therapeutics, Inc. Enhancing hematopoietic progenitor cell engraftment using mesenchymal stem cells
US5843425A (en) * 1992-02-19 1998-12-01 The General Hospital Corporation Transplantation and graft-versus-host-disease
WO1993018648A1 (en) * 1992-03-23 1993-09-30 Baxter International Inc. In vitro-derived human neutrophil precursor cells
US5382514A (en) 1992-03-31 1995-01-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services In vivo angiogenesis assay
US6653134B2 (en) 1995-03-28 2003-11-25 Cp Hahnemann University Isolated stromal cells for use in the treatment of diseases of the central nervous system
ATE329603T1 (de) 1995-03-28 2006-07-15 Univ Jefferson Implantat mit immunisolierten stromazellen und deren verwendung
US6974571B2 (en) * 1995-03-28 2005-12-13 Thomas Jefferson University Isolated stromal cells and methods of using the same
JP2000508922A (ja) * 1996-04-26 2000-07-18 ケース ウエスターン リザーブ ユニバーシティ 間葉幹細胞を用いる皮膚再生
US6165785A (en) 1996-05-24 2000-12-26 University Of Cincinnati Bone marrow cultures for developing suppressor and stimulator cells for research and therapeutic applications
CA2271758A1 (en) * 1996-11-15 1998-05-22 Osiris Therapeutics, Inc. Msc-megakaryocyte precursor composition and method of isolating mscs associated with isolated megakaryocytes by isolating megakaryocytes
US20030103951A1 (en) 1997-07-14 2003-06-05 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
US6077987A (en) * 1997-09-04 2000-06-20 North Shore-Long Island Jewish Research Institute Genetic engineering of cells to enhance healing and tissue regeneration
AU749675B2 (en) * 1998-03-13 2002-07-04 Mesoblast International Sarl Uses for human non-autologous mesenchymal stem cells
US6328960B1 (en) * 1998-03-18 2001-12-11 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
US20030118567A1 (en) * 1999-03-26 2003-06-26 Stewart Duncan John Cell-based therapy for the pulmonary system
PT1066060E (pt) * 1998-04-03 2003-12-31 Osiris Therapeutics Inc Celulas estaminais mesenquimais como imunossupressores
AU2904199A (en) * 1998-04-03 1999-10-25 Osiris Therapeutics, Inc. Use of human mesenchymal stem cells to induce t-cell apoptosis
US6835377B2 (en) * 1998-05-13 2004-12-28 Osiris Therapeutics, Inc. Osteoarthritis cartilage regeneration
DE69937888T2 (de) * 1998-07-31 2009-01-02 Genzyme Corp., Cambridge Verfahren zur Herstellung mesenchymaler Stammzellen
AU2998300A (en) * 1999-02-17 2000-09-04 United States Surgical Corporation Genetically altered mesenchymal stem cells and methods of use thereof
US20050153442A1 (en) * 1999-03-10 2005-07-14 Adam Katz Adipose-derived stem cells and lattices
KR100979664B1 (ko) * 1999-03-10 2010-09-02 유니버시티 오브 피츠버그 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 지방 유래 간세포 및 격자
US8017112B2 (en) 1999-05-14 2011-09-13 Henry Ford Health System Transplantation of bone marrow stromal cells for treatment of neurodegenerative diseases
US6685936B2 (en) 1999-10-12 2004-02-03 Osiris Therapeutics, Inc. Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation
WO2001060348A2 (en) † 2000-02-18 2001-08-23 Cv Therapeutics, Inc. Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
EP1261694B1 (en) 2000-02-26 2008-01-16 Artecel, Inc. Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof
US6936281B2 (en) * 2001-03-21 2005-08-30 University Of South Florida Human mesenchymal progenitor cell
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
WO2002008389A2 (en) * 2000-07-26 2002-01-31 Scimed Life Systems, Inc. Therapeutic angiogenesis by bone marrow-derived cell transplantation in myocardial ischemic tissue and skeletal muscle ischemic tissue
US20020045260A1 (en) * 2000-10-17 2002-04-18 Shih-Chieh Hung Method of isolating mesenchymal stem cells
CA2438047A1 (en) * 2001-02-14 2002-08-22 Hildegard M. Kramer Biocompatible fleece for hemostasis and tissue engineering
CN100516204C (zh) 2001-04-24 2009-07-22 味之素株式会社 干细胞及其分离方法
US6549704B2 (en) 2001-06-26 2003-04-15 Corning Incorporated Fabrication of microlensed fiber using doped silicon dioxide
US6905678B2 (en) * 2001-07-07 2005-06-14 Crucell Holland B.V. Gene delivery vectors with cell type specificity for mesenchymal stem cells
EP1279738A1 (en) * 2001-07-06 2003-01-29 Crucell Holland B.V. Gene delivery vectors with cell type specificity for mesenchymal stem cells
WO2003010305A1 (en) * 2001-07-27 2003-02-06 Arhus Amt Immortilized stem cells
WO2003018077A1 (en) * 2001-08-22 2003-03-06 National Institute Of Advanced Industrial Science And Technology Method of bone regeneration
US20030104997A1 (en) 2001-09-05 2003-06-05 Black Ira B. Multi-lineage directed induction of bone marrow stromal cell differentiation
KR20090115984A (ko) 2001-11-09 2009-11-10 아르테셀 사이언스, 인크. 지방 조직에서 유래된 기질세포의 내분비 췌장 분화 및 이의 용도
US6939863B2 (en) 2002-01-04 2005-09-06 Wei-Jan Chen Prevention of atherosclerosis and restenosis
AU2003202988A1 (en) * 2002-01-14 2003-07-30 The Board Of Trustees Of The University Of Illinois Use of modified pyrimidine compounds to promote stem cell migration and proliferation
BR0306902A (pt) * 2002-01-14 2006-04-11 Ford Henry Health System materiais de células estromais de medula óssea para uso na formação de vasos sanguìneos e produção de fatores angiogênicos e tróficos
US20030161815A1 (en) 2002-02-12 2003-08-28 Intercytex Limited Cell delivery system
AUPS112802A0 (en) 2002-03-15 2002-04-18 Monash University Methods of inducing differentiation of stem cells into a specific cell lineage
US7282222B2 (en) * 2002-03-15 2007-10-16 The United States Of America As Represented By The Department Of Veterans Affairs Methods and compositions for directing cells to target organs
WO2003078567A2 (en) * 2002-03-18 2003-09-25 Gamida-Cell Ltd. Methods of inducing differentiation in ex vivo expanded stem cells
AU2003220966A1 (en) * 2002-04-03 2003-10-13 Naohide Yamashita Drug containing human placenta-origin mesenchymal cells and process for producing vegf using the cells
ITTO20020311A1 (it) 2002-04-10 2003-10-10 Medestea Int Spa Procedimento per la preparazione di cellule staminali da tessuto muscolare e tessuto adiposo umano e cellule staminali ottenibili mediante t
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
CN1187058C (zh) * 2002-04-16 2005-02-02 中国医学科学院血液学研究所泰达生命科学技术研究中心 用于修复中枢神经损伤的干细胞制剂及其制造方法
US7628988B2 (en) 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
US20040009155A1 (en) * 2002-07-12 2004-01-15 Maria Palasis Method for sustaining direct cell delivery
JP2005532810A (ja) * 2002-07-16 2005-11-04 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム 組織修復および組織形成のために間葉性幹細胞を移植する方法
AU2003259152A1 (en) 2002-07-23 2004-02-09 Boston Scientific Limited Cell therapy for regeneration
JP2005534345A (ja) * 2002-07-29 2005-11-17 エス セル インターナショナル ピーティーイー リミテッド インスリン陽性、グルコース応答性細胞の分化のための多段階方法
US7732203B2 (en) 2002-08-17 2010-06-08 Ajoll University Industry Cooperation Foundation Method for transdifferentiating mesenchymal stem cells into neuronal cells
US20060110359A1 (en) * 2002-09-06 2006-05-25 Juan Sanchez-Ramos Cellular delivery of natriuretic peptides
KR20040022134A (ko) * 2002-09-06 2004-03-11 송준석 인간 간엽줄기 세포와 p53 분비 아데노바이러스를 이용한항암치료방법
WO2004084950A2 (en) * 2003-03-24 2004-10-07 Case Western Reserve University Cell targeting methods and compositions
CN1536075A (zh) * 2003-04-09 2004-10-13 中国人民解放军军事医学科学院野战输 一种诱导骨髓间充质干细胞向胰岛样细胞分化的方法
WO2005001080A2 (en) * 2003-06-27 2005-01-06 Ethicon, Incorporated Postpartum-derived cells for use in treatment of disease of the heart and circulatory system
WO2005013885A2 (en) * 2003-08-07 2005-02-17 Healor Ltd. Pharmaceutical compositions and methods for accelerating wound healing
US6974991B2 (en) * 2003-10-29 2005-12-13 International Business Machines Corp. DRAM cell with buried collar and self-aligned buried strap
CN100581095C (zh) * 2003-11-20 2010-01-13 爱德万测试株式会社 时钟恢复电路以及通讯装置
TR201901268T4 (tr) * 2004-03-22 2019-02-21 Mesoblast Int Sarl Mezenkimal kök hücreleri ve bunların kullanımları.
EP3461884B1 (en) 2004-03-22 2025-05-28 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
US20080095749A1 (en) 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
JP4326462B2 (ja) * 2004-11-19 2009-09-09 富士通株式会社 半導体集積回路の設計を支援する設計支援装置、設計支援プログラム、及び設計支援方法
US7405186B2 (en) 2005-03-25 2008-07-29 Chemsil Silicones, Inc. Lubricant compositions, condom products and methods of making same
JP5162756B2 (ja) 2005-04-14 2013-03-13 財団法人ヒューマンサイエンス振興財団 医薬組成物及びその製造方法
TWM290409U (en) * 2005-10-14 2006-05-11 Ming Shiau Retractable barbeque rack
US20070253931A1 (en) 2006-01-12 2007-11-01 Osiris Therapeutics, Inc. Use of mesenchymal stem cells for treating genetic diseases and disorders
US20070258963A1 (en) 2006-01-13 2007-11-08 Osiris Therapeutics, Inc. Mesenchymal stem cells expressing TNF-alpha receptors
US20090274665A1 (en) 2006-04-27 2009-11-05 Cell Therapy Technologies, Inc. Stem Cells For Treating Lung Diseases
RU2416179C2 (ru) 2006-10-06 2011-04-10 Конинклейке Филипс Электроникс Н.В. Устройство снабжения энергией световых элементов и способ подвода мощности к световым элементам
US8029805B2 (en) 2008-07-25 2011-10-04 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Recombinant B. pseudomallei adhesin protein and methods and uses thereof
EP3124601A1 (en) 2008-08-14 2017-02-01 Mesoblast International Sàrl Purified mesenchymal stem cell compositions and methods of purifying mesenchymal stem cell compositions
US20120087868A1 (en) 2010-10-08 2012-04-12 Gabriele Todd Nanoparticle-loaded cells

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6048933A (ja) * 1983-08-29 1985-03-16 Green Cross Corp:The ガンマ−・インタ−フェロン組成物
JP2004506598A (ja) * 1999-10-26 2004-03-04 オシリス　セラピューティクス，インコーポレイテッド 移植における免疫応答の予防および処置に適した間葉幹細胞から獲得した上澄み
JP2003520254A (ja) * 2000-01-19 2003-07-02 エス． ジル，パーカッシュ アンチセンスｖｅｇｆオリゴヌクレオチドに関する方法および組成物
JP2004507454A (ja) * 2000-04-25 2004-03-11 オシリス　セラピューティクス，インコーポレイテッド 間葉幹細胞を用いる関節修復
JP2003137898A (ja) * 2002-08-01 2003-05-14 Hayashibara Biochem Lab Inc 免疫担当細胞においてインターフェロン−γの産生を誘導する因子（ＩＧＩＦ）
JP2006510675A (ja) * 2002-12-05 2006-03-30 ケース ウエスタン リザーブ ユニバーシティ 虚血の細胞ベースの治療

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011505860A (ja) * 2007-12-21 2011-03-03 ボーン セラピューティクス エス．アー． 炎症性リウマチ性疾患の治療におけるヒト骨形成細胞
JP2009242265A (ja) * 2008-03-28 2009-10-22 Jcr Pharmaceuticals Co Ltd アトピー性皮膚炎治療剤
JP2018080174A (ja) * 2008-08-04 2018-05-24 ティジェニクス エス．エー．ユー． 間葉系幹細胞の使用
JP2011529957A (ja) * 2008-08-04 2011-12-15 セレリックス エスエー 間葉系幹細胞の使用
JP2016040256A (ja) * 2008-08-04 2016-03-24 ティジェニクス エス．エー．ユー． 間葉系幹細胞の使用
JP2013526839A (ja) * 2009-12-08 2013-06-27 ザ ボード オブ トラスティーズ オブ ザ ユニバシティ オブ イリノイズ 幹細胞免疫変調の使用方法及び装置
JP2016516985A (ja) * 2013-03-15 2016-06-09 ティゲニクス、エセ、ア、ウＴｉＧｅｎｉｘ，Ｓ．Ａ．Ｕ． 細胞治療に対する臨床反応を決定するためのリンパ球バイオマーカー
JP2016540969A (ja) * 2013-11-04 2016-12-28 ベクトン・ディキンソン・アンド・カンパニーＢｅｃｔｏｎ， Ｄｉｃｋｉｎｓｏｎ Ａｎｄ Ｃｏｍｐａｎｙ 多能性間質細胞集団の免疫調節ポテンシャル
WO2017221879A1 (ja) * 2016-06-20 2017-12-28 富士フイルム株式会社 トロフィックファクタ放出剤および炎症疾患処置剤
JPWO2017221879A1 (ja) * 2016-06-20 2019-04-25 富士フイルム株式会社 トロフィックファクタ放出剤および炎症疾患処置剤
US10980858B2 (en) 2016-06-20 2021-04-20 Fujifilm Corporation Trophic factor releasing agent and inflammatory disease treating agent
JP7212371B2 (ja) 2016-09-07 2023-01-25 エスシーエム ライフサイエンス カンパニー リミテッド 炎症刺激された間葉系幹細胞を含む免疫疾患または炎症疾患の予防または治療用薬学的組成物
JP2019531281A (ja) * 2016-09-07 2019-10-31 エスシーエム ライフサイエンス カンパニー リミテッド 炎症刺激された間葉系幹細胞を含む免疫疾患または炎症疾患の予防または治療用薬学的組成物
WO2019146131A1 (ja) * 2018-01-24 2019-08-01 学校法人順天堂大学 間葉系幹細胞による処置の効果を増幅するための組成物
JP2021526135A (ja) * 2018-06-05 2021-09-30 メディポスト・カンパニー・リミテッドＭｅｄｉｐｏｓｔ Ｃｏ．， Ｌｔｄ． 有効成分として間葉系幹細胞を含む炎症性疾患の予防又は治療のための医薬組成物
JP7480454B2 (ja) 2018-06-05 2024-05-10 メディポスト・カンパニー・リミテッド 有効成分として間葉系幹細胞を含む炎症性疾患の予防又は治療のための医薬組成物
JP2022528827A (ja) * 2019-03-15 2022-06-16 フラウンホーファー－ゲゼルシャフト ツゥア フェアデルング デア アンゲヴァンドテン フォァシュング エー．ファウ． 体外免疫寛容増強血液治療のための治療装置及び方法
JP7529682B2 (ja) 2019-03-15 2024-08-06 フラウンホーファー－ゲゼルシャフト ツゥア フェアデルング デア アンゲヴァンドテン フォァシュング エー．ファウ． 体外免疫寛容増強血液治療のための治療装置及び方法
JP2022035914A (ja) * 2020-08-21 2022-03-04 遵義医科大学附属医院 高速かつ効率的にインビトロ増幅ヒト間葉系幹細胞的方法および使用
JP7038782B2 (ja) 2020-08-21 2022-03-18 遵義医科大学附属医院 高速かつ効率的にインビトロ増幅ヒト間葉系幹細胞的方法および使用

Also Published As

Publication number Publication date
EP2298862B1 (en) 2017-08-30
US20090180997A1 (en) 2009-07-16
WO2008042174A2 (en) 2008-04-10
US10716814B2 (en) 2020-07-21
AU2010200916A1 (en) 2010-04-01
CA2659825A1 (en) 2008-04-12
US10828334B1 (en) 2020-11-10
AU2009200019A1 (en) 2009-02-05
EP1974016A4 (en) 2009-04-01
EP3461884A1 (en) 2019-04-03
KR20090065478A (ko) 2009-06-22
CN101384702A (zh) 2009-03-11
US9943547B2 (en) 2018-04-17
EP2298861A3 (en) 2011-11-30
CA2564679C (en) 2015-06-23
WO2005093044A1 (en) 2005-10-06
US20150017132A1 (en) 2015-01-15
WO2008042174A3 (en) 2008-06-19
US20100172885A1 (en) 2010-07-08
EP2243826A2 (en) 2010-10-27
US20110142807A1 (en) 2011-06-16
US20090208463A1 (en) 2009-08-20
US20190175657A1 (en) 2019-06-13
EP2298864B1 (en) 2017-10-11
EP1974016A2 (en) 2008-10-01
US20190240259A1 (en) 2019-08-08
EP2298863B1 (en) 2015-07-22
EP2824174B1 (en) 2018-11-28
AU2009200019B2 (en) 2012-08-02
EP2298864A3 (en) 2011-11-23
EP2824175B1 (en) 2017-11-29
US20150272997A1 (en) 2015-10-01
US10729727B2 (en) 2020-08-04
US11389484B2 (en) 2022-07-19
US10960025B2 (en) 2021-03-30
US20080213227A1 (en) 2008-09-04
EP1727892A1 (en) 2006-12-06
US10668101B2 (en) 2020-06-02
US20110027238A1 (en) 2011-02-03
US20140154276A1 (en) 2014-06-05
US20140161776A1 (en) 2014-06-12
AU2005227295A1 (en) 2005-10-06
EP2298863A3 (en) 2011-04-13
EP2824174A1 (en) 2015-01-14
EP2243826A3 (en) 2013-11-06
EP2824175A3 (en) 2015-05-06
US20110318314A1 (en) 2011-12-29
EP1727892B1 (en) 2012-05-02
US9694035B2 (en) 2017-07-04
EP2298864A2 (en) 2011-03-23
JP2010505764A (ja) 2010-02-25
US20230076630A1 (en) 2023-03-09
US20140328807A1 (en) 2014-11-06
EP2824175A2 (en) 2015-01-14
EP2298861A2 (en) 2011-03-23
US20200360442A1 (en) 2020-11-19
EP2298863A2 (en) 2011-03-23
EP2298862A2 (en) 2011-03-23
US20110311496A1 (en) 2011-12-22
EP1727892A4 (en) 2007-08-22
EP2824175B2 (en) 2020-10-28
US20050239897A1 (en) 2005-10-27
US20190201447A1 (en) 2019-07-04
US20200246387A1 (en) 2020-08-06
US20110318315A1 (en) 2011-12-29
EP2298862A3 (en) 2011-08-24
EP3461884B1 (en) 2025-05-28
CA2564679A1 (en) 2005-10-06
EP2298861B1 (en) 2017-09-13

Similar Documents

Publication Publication Date Title
US11389484B2 (en) Mesenchymal stem cells and uses therefor
JP7546239B2 (ja) 間葉幹細胞及びその使用法
JP2014139214A (ja) 間葉系幹細胞とその用途
AU2023204145A1 (en) Mesenchymal stem cells and uses therefor
HK1262056A1 (en) Mesenchymal stem cells and uses therefor
HK1205531B (en) Mesenchymal stem cells and uses therefor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080307

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080307

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20080902

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110426

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110727

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120315

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120411

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20120525